Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00235963 · ClinicalTrials.gov registry record · Phase 1

A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm

A Phase 1 study of Subarachnoid Hemorrhage and Delayed Vasospasm, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 1
Development phase
104
Enrollment target
1
Study location

NCT00235963 is a Phase 1 study of Subarachnoid Hemorrhage and Delayed Vasospasm that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 104 participants, below the 3,583-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00235963, a Phase 1 study of Subarachnoid Hemorrhage and Delayed Vasospasm, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 1
Development phase
104 participants
Enrollment target
1
Study location

Study Summary

To determine whether HMG-CoA reductase inhibitor simvastatin prevents or ameliorates subarachnoid hemorrhage-induced delayed vasospasm and its ischemic consequences.

Interventions

  • DRUG Simvastatin

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2002-12
Est. Completion 2006-02
Phase Phase 1

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT00235963

The ClinicalTrials.gov registry entry for NCT00235963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,583-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (97% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Simvastatin is the first listed.

NCT00235963 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00235963 about?

NCT00235963 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm". To determine whether HMG-CoA reductase inhibitor simvastatin prevents or ameliorates subarachnoid hemorrhage-induced delayed vasospasm and its ischemic consequences.

What is the current status of trial NCT00235963?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2002-12. Estimated completion is 2006-02.

What conditions does trial NCT00235963 study?

This clinical trial studies the following conditions: Subarachnoid Hemorrhage, Delayed Vasospasm.

What interventions are being tested in trial NCT00235963?

The interventions under investigation include: Simvastatin (DRUG).

Who is sponsoring clinical trial NCT00235963?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00235963 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Subarachnoid Hemorrhage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.